Theratechnologies sales and marketing update

Theratechnologies said on Feb. 14 that it expects inventory of Egrifta tesamorelin to be depleted "in the coming weeks" due to manufacturing delays and production issues and that it would temporarily cease manufacture of Egrifta. The analog of growth hormone-releasing factor is approved to treat excess abdominal fat in HIV patients with lipodystrophy. The company said it is investigating the causes of the issues and that it is unable to determine a timeline for when it would resume manufacturing. ...